IBM’s AI Paradox: How a Memory-Chip Squeeze Triggered the Worst Trading Day in a Century
Published on 07/25/2026 at 04:51 | Redaktion boerse-global.de
The arithmetic is brutal and, for a company that has weathered depressions, wars, and the dot-com bust, almost surreal. On July 14, 2026, IBM shares lost a quarter of their value in a single session — a 25% collapse that eclipsed even the 23.7% rout of Black Monday in 1987. But the culprit wasn’t a broken business model or a sudden loss of relevance. It was the soaring price of memory chips.
When AI’s Appetite Starves the Cash Cow
CEO Arvind Krishna offered a stark diagnosis: corporate customers are pouring their budgets into high-end AI hardware, driving up the cost of memory and storage components by 15% to 30%. The money that would have gone toward IBM software and infrastructure is instead being swallowed by the AI arms race. The result was a second-quarter revenue miss of roughly $600 million — $17.2 billion against Wall Street’s $17.86 billion estimate.
The damage was most acute in IBM’s crown jewel, the Z-mainframe business, where revenues cratered by 42% in the quarter. That’s not a cyclical dip; it’s a structural collision between IBM’s legacy strength and its own growth market. “What happened was worse than our expectations,” Krishna admitted. “We didn’t adapt quickly enough.”
A Technical Bounce, Not a Turnaround
After the initial shock, the stock drifted near multi-month lows, touching a 52-week trough of €175.14 on Thursday — more than 35% below its early-June peak. By Friday, however, buyers stepped in, pushing shares up 3.74% to €188.38. The relative strength index had fallen to 35.5, deep in oversold territory, and options traders responded by loading up on calls, betting on stabilization after the freefall.
Should investors sell immediately? Or is it worth buying IBM?
Yet the relief rally looks more like a dead-cat bounce than the start of a sustained recovery. The stock remains nearly 20% below its 200-day moving average, and annualized volatility of roughly 85% leaves the door open for sharp moves in either direction. “This is a technical bounce with a legitimate foundation,” one market observer noted, “but not confirmation that the sell-off is over.”
The Deals That Will Define the Recovery
Krishna has staked his credibility on a recovery in deferred business. According to the CEO, one-third of the deals that slipped in the second quarter were closed in the first three weeks of July, and he expects to recapture roughly 80% of them by year-end. That claim is now the single most important data point for IBM’s near-term trajectory.
The full quarterly numbers, released midweek, offered some bright spots. Software revenue rose 5%, with Red Hat climbing 11% and the data business surging 19%. Consulting held steady. Free cash flow guidance remained unchanged. But the infrastructure business — mainframe included — continues to bleed, and the memory-chip shortage that triggered the rout shows no signs of easing quickly.
A Lower Bar, but a Higher Hurdle
IBM has trimmed its 2026 revenue growth forecast to 4% to 5% in constant currency, down from prior expectations. The stock’s year-to-date loss stands at 27.52%, though the 12-month decline is a milder 14.99% — a reminder that the current crisis is acute and AI-driven, not a chronic erosion of the core business.
Analysts remain cautiously optimistic, with a consensus price target of €231.11, implying 22.7% upside from Friday’s close. That target, however, was set before the full impact of the guidance cut was absorbed, and downward revisions are likely in the coming days. Several law firms are also probing potential securities-fraud claims related to the profit warning, adding a layer of legal uncertainty.
IBM at a turning point? This analysis reveals what investors need to know now.
The Quantum Card
While the market fixates on mainframe woes, IBM is playing a long game. On July 23, the company announced a binding agreement to acquire HRL Laboratories, previously owned by Boeing and General Motors. The deal brings expertise in silicon-spin qubits, complementing IBM’s existing work on superconducting qubits, and supports a $10 billion-plus commitment to quantum research over five years. The goal: a fault-tolerant machine called “Quantum Starling” by 2029.
That vision, however, offers little comfort to investors watching the current quarter’s pipeline. The real test for IBM is whether those delayed deals turn into signed contracts — or whether the AI hardware squeeze has permanently reshaped corporate spending priorities. Until then, the stock remains a mirror of an unusual conflict: a technology giant being undercut by the very market it helped create.
Ad
IBM Stock: New Analysis - 25 July
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
